Dr. Lal Pathlabs Limited — Earnings Release 2019

May 17, 2019

==> picture [23 x 36] intentionally omitted <==

==> picture [251 x 29] intentionally omitted <==

May 17, 2019

The National Stock Exchange of India Limited Exchange Plaza Sandra Kurla Complex, Sandra (E) Mumbai - 400051

The Bombay Stock Exchange Limited 15[th ] Floor, Phiroze Jeejeeboy Towers Dalal Street, Mumbai - 400001

Subject: Press Release for Audited Financial Results (Standalone and Consolidated) for the Quarter and Financial Year ended March 31, 2019.

Dear Sir/Madam,

Please find enclosed herewith the Press Release for the Audited Financial Results (Standalone and Consolidated) for the Quarter and Financial Year ended March 31, 2019.

You are requested to take note of the above.

Thanking You,

Yours Faithfully,

• ./ Company Secretary and Legal Head

Encl: As above

Regd. Office: Or. Lal Pathlabs ltd. Blnr� E, Secror-18, Rohini, New Delhi - 1 JQ,1135. +91-11-30258'.J!O. Fa><: +91-11-2788-2134 Corporate Office: Dr. Lal Pathlabs Ltd., I 2U1 Floo� Tower 8, SAS Tower, Ml't1,city, Sector-38, Gurugram - 122 00 I, Haryana -r9 l-124-3016-500. Fa,c: + 91- I 24-4234-463 E-mail: lalpathJ�t,5•�falpathlahs.com, Web: www.lalpattllabs.com, CIN No.: L748 l"JDll 'rt�PLC065? 2:3

==> picture [150 x 35] intentionally omitted <==

For Immediate Release

May 17, 2019

Dr. Lal PathLabs Limited records revenue growth of 12.9% to Rs 3,011 million in Q4 FY2018-19 Full year revenue grows 13.9% to Rs 12,034 million

New Delhi, India, May 17, 2019 – Dr. Lal PathLabs Limited (referred to as the “Company”; NSE: LALPATHLAB, BSE: 539524), a leading diagnostic and related healthcare service provider announces their financial results for the quarter & financial year ended March 31, 2019

Consolidated Performance Highlights: Q4FY2018-19 vs Q4FY2017-18 Revenue growth: 12.9% at Rs 3,011 million, Normalised EBITDA at Rs 729 million, PBT at Rs 692 million Normalised EBITDA margins at 24.2% vs 25.8% in Q4 last year and PAT Rs 474 million with margin at 15.7% Final Dividend Rs 3.50 per share recommended  Revenue increased by 12.9% in Q4 to Rs 3,011 million vs Rs 2,668 million in the previous year same quarter. Underlying volume growth is 12.5% during the quarter. For the full year FY19 revenue grew 13.9% to Rs 12,034 million, full year volume growth at 15.3%

• Normalised EBITDA for Q4 FY19 is at Rs729 million from Rs 688 million in the same quarter last year, after adjustment for stock based compensation costs and CSR expense. Full year normalised EBITDA grew 12.5% to Rs 3,132 million

• Normalised EBITDA Margin at 24.2% for Q4 FY19 vs 25.8% in Q4 FY18 and for the full year normalised EBITDA margins are 26%

• PBT is at Rs 692 million in Q4 vs Rs 620 million in Q4 last year. The full year PBT increased from Rs. 2,613 million to Rs. 3,006 million a growth of 15%

• Profit after Tax in Q4 FY19 at Rs 474 million as compared to Rs 402 million in Q4 last year. Full year PAT is at Rs 2,005 million a growth of 16.7% over last year

• Final Dividend of Rs 3.50 per equity share of Rs 10 each recommended. This is in addition to the interim dividend of Rs 2.50 already paid out. The total dividend for the year is Rs 6.00 per equity share

Financial Overview (Consolidated) in Rs million

==> picture [436 x 191] intentionally omitted <==

Dr. Lal Pathlabs Limited 12[th] Floor, Tower-B, SAS Tower, Sector-38, Medicity, Gurgaon 122001, Phone: +91 124 3016500, website: www.lalpathlabs.com

1

==> picture [150 x 35] intentionally omitted <==

About Dr. Lal PathLabs Limited

Dr. Lal PathLabs is a provider of diagnostic and related healthcare tests and services in India. Through its integrated, nationwide network, the company offer patients and healthcare providers a broad range of diagnostic and related healthcare tests and services for use in core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions.

As on March 31, 2019 the company has 200 clinical laboratories (including National Reference Lab at Delhi & Regional Reference Lab at Kolkata), 2,569 Patient Service Centers (PSCs) and 6,426 Pick-up Points (PUPs). It’s customers include individual patients, hospitals and other healthcare providers and corporate customers.

Contact Details

Ved Prakash Goel +91 124 3016500 Chief Financial Officer cfo@lalpathlabs.com Dr. Lal PathLabs Limited +91 9811177405 Aparna Agarwal aparna.agarwal@adfactorspr.com Adfactors PR

For further information on Dr. Lal PathLabs see www.lalpathlabs.com

Safe Harbour

This release contains statements that contain “forward looking statements” including, but without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to Dr. Lal PathLabs future business developments and economic performance. While these forward looking statements indicate our assessment and future expectations concerning the development of our business, a number of risks, uncertainties and other unknown factors could cause actual developments and results to differ materially from our expectations. These factors include, but are not limited to, general market, macro-economic, governmental and regulatory trends, movements in currency exchange and interest rates, competitive pressures, technological developments, changes in the financial conditions of third parties dealing with us, legislative developments, and other key factors that could affect our business and financial performance. Dr. Lal PathLabs undertakes no obligation to publicly revise any forward looking statements to reflect future / likely events or circumstances.

Dr. Lal Pathlabs Limited

12[th] Floor, Tower-B, SAS Tower, Sector-38, Medicity, Gurgaon 122001, Phone: +91 124 3016500, website: www.lalpathlabs.com

2